sichenzia_sc13d-090908.htm
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE
13D
(Rule
13d-101)
INFORMATION
TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO
RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE
13d-2(a)
(Amendment
No. )1
GRANT
LIFE SCIENCES, INC.
(Name of
Issuer)
Common
Stock, par value $.01 per share
(Title of
Class of Securities)
388113102
(CUSIP
Number)
(Name,
Address and Telephone Number of Person
Authorized
to Receive Notices and Communications)
September
9, 2008
(Date of
Event Which Requires Filing of This Statement)
If the
filing person has previously filed a statement on Schedule 13G to report the
acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box o.
Note. Schedules
filed in paper format shall include a signed original and five copies of the
schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom
copies are to be sent.
Hun-Chi
Lin
1787 E.
Fort Union Blvd.
Suite
202
Salt Lake
City, UT 84121
(Continued
on following pages)
1The
remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The
information required on the remainder of this cover page shall be deemed to be
“filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or
otherwise subject to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however, see the
Notes)
CUSIP
No. 388113102
|
13D
|
Page
2 of 4 Pages
|
1
|
NAME
OF REPORTING
PERSONS Gregory
Sichenzia
I.R.S.
IDENTIFICATION NOS. OF ABOVE
PERSONS Not
applicable
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A
GROUP* (a)
¨
(b)
¨
|
3
|
SEC
USE ONLY
|
4
|
SOURCE
OF
FUNDS* OO
|
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d)
or 2(e) ¨
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
US
|
NUMBER
OF
SHARES
|
7
|
SOLE
VOTING POWER
38,600,000
shares of common stock.
|
BENEFICIALLY
OWNED
BY
|
8
|
SHARED
VOTING POWER
0
|
EACH
REPORTING
|
9
|
SOLE
DISPOSITIVE POWER
38,600,000
shares of common stock.
|
PERSON
WITH
|
10
|
SHARED
DISPOSITIVE POWER
0
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
38,600,000
shares of common stock.
|
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* ¨
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.02%
|
14
|
TYPE
OF REPORTING PERSON*
IN
|
Item
1. Security and Issuer.
This
statement relates to shares of the common stock, par value $.001 per share, of
Grant Life Sciences, Inc., a Nevada corporation (the “Company”). The
Company has its principal executive office at 1787 E. Fort Union Blvd., Suite
202, Salt Lake City, UT 84121.
Item
2. Identity and Background.
This
statement is being filed by Gregory Sichenzia, a United States
citizen. Mr. Sichenzia is legal counsel to the Company and maintains
an office at Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor,
New York, New York 10006.
On August
27, 2008, the Board of Directors of the Company approved the issuance of
38,600,000 shares of the Company’s common stock to Mr. Sichenzia as compensation
for his legal services. Mr. Sichenzia was issued the 38,600,000
shares on September 9, 2008.
During
the past five years, Mr. Sichenzia has not been (a) convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors, if any), or
(b) been a party to a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result thereof was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or finding any
violation with respect to such laws.
Item
3. Source and Amount of Funds or Other Consideration.
The sole source of consideration for
the issuance of 38,600,000 shares of the Company’s common stock to Mr. Sichenzia
is his legal services to the Company.
Item
4. Purpose of Transaction.
See Item
2 above.
Item
5. Interest in Securities of the Issuer.
Under the
rules and regulations of the Securities and Exchange Commission, Mr. Sichenzia
beneficially owned 38,600,000 shares of common stock, representing 9.02% of the
outstanding shares of common stock of the Company as of September 9,
2008. The percentage of outstanding shares of common stock is
computed based on 427,940,665 shares of common stock outstanding as of September
9, 2008. Except for the transactions described herein, Mr. Sichenzia
has no plans, arrangements or agreements for the acquisition or issuance of
additional shares of the Company’s common stock or other securities convertible
into equity securities of the Company.
Item
6. Contracts, Arrangements, Understandings or Relationships with
Respect to Securities of the Issuer.
None.
Item
7. Material to be Filed as Exhibits.
SIGNATURES
After reasonable inquiry and to the
best of my knowledge and belief, I certify that the information set forth in
this statement is true, complete and accurate.
|
|
|
|
|
|
|
September
9, 2008
|
|
/s/ Gregory
Sichenzia |
|
|
|
Gregory
Sichenzia |
|
|
|
|
|
|
|
|
|
(Page 4
of 4 Pages)